(Q37056369)

18 August 2017

1 reference

title

Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand (English)

1 reference

18 August 2017

Toshimasa Itoh

1

1 reference

PubMed ID

18193404

18 August 2017

Keiko Yamamoto

series ordinal

2

1 reference

PubMed ID

18193404

18 August 2017

language of work or name

1 reference

8 January 2008

1 reference

Naunyn-Schmiedeberg's Archives of Pharmacology

18 August 2017

1 reference

18 August 2017

377

1 reference

18 August 2017

4-6

1 reference

18 August 2017

541-547

1 reference

https://scigraph.springernature.com/pub.10.1007/s00210-007-0251-x

18 August 2017

0 references

cites work

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00210-007-0251-X

21 January 2018

The PPAR resource page.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00210-007-0251-X

21 January 2018

1 reference

12 December 2020

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

1 reference

12 December 2020

Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen

1 reference

12 December 2020

Serum free fatty acid pattern and risk of myocardial infarction: a case-control study

1 reference

12 December 2020

Conformationally Restricted Analogs of 1α,25-Dihydroxyvitamin D3and Its 20-Epimer: Compounds for Study of the Three-Dimensional Structure of Vitamin D Responsible for Binding to the Receptor

1 reference

12 December 2020

Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors

1 reference

12 December 2020

Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease.

1 reference

12 December 2020

Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease

1 reference

12 December 2020

Angiotensin II, atherosclerosis, and aortic aneurysms

1 reference

12 December 2020

Angiotensin II, PPAR-gamma and atherosclerosis

1 reference

12 December 2020

Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects

1 reference

12 December 2020

Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity

1 reference

12 December 2020

Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease

1 reference

12 December 2020

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

1 reference

12 December 2020

New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

1 reference

12 December 2020

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

1 reference

12 December 2020

Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2

1 reference

12 December 2020

Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents

1 reference

12 December 2020

The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

1 reference

12 December 2020

Bifunctional properties of peroxisome proliferator-activated receptor gamma1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3.

1 reference

12 December 2020

PPARgamma and atherosclerosis

1 reference

12 December 2020

Hic-5 regulates an epithelial program mediated by PPARgamma

1 reference

12 December 2020

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

1 reference

12 December 2020

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

1 reference

12 December 2020

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer

1 reference

12 December 2020

Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents

1 reference

12 December 2020

Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism

1 reference

12 December 2020

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

1 reference

12 December 2020

Microglia and the immune pathology of Alzheimer disease

1 reference

12 December 2020

Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization

1 reference

12 December 2020

PPARgamma as a new therapeutic target in inflammatory bowel diseases

1 reference

12 December 2020

Bone is a target for the antidiabetic compound rosiglitazone.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma in malignant diseases.

1 reference

12 December 2020

The organization, promoter analysis, and expression of the human PPARgamma gene

1 reference

12 December 2020

Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.

1 reference

12 December 2020

PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1

1 reference

12 December 2020

Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.

1 reference

12 December 2020

Thiazolidinedione use and bone loss in older diabetic adults

1 reference

12 December 2020

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

12 December 2020

Synergy between PPARgamma ligands and platinum-based drugs in cancer

1 reference

12 December 2020

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

1 reference

12 December 2020

Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

1 reference

12 December 2020

Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

1 reference

12 December 2020

The role of glial reaction and inflammation in Parkinson's disease.

1 reference

12 December 2020

Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice

1 reference

12 December 2020

10.1007/S00210-007-0251-X

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18193404